SINPHAR Business Summary

Sinphar Pharmaceutical Co., Ltd. (1734.TW) operates a vertically integrated business model centered on the research, development, and manufacturing of generic pharmaceuticals, over-the-counter (OTC) drugs, and high-margin functional health supplements. Revenue is primarily generated through direct product sales to healthcare institutions and retail pharmacies, supplemented by contract development and manufacturing organization (CDMO) services and active pharmaceutical ingredient (API) production via its subsidiary network. The company’s operations are segmented into three core pillars: therapeutic pharmaceuticals (focusing on oncology, dermatology, and cardiovascular treatments), the "Sinphar Tian-Li" botanical health food division, and a specialized cosmetics branch. Within the Taiwanese pharmaceutical landscape, Sinphar maintains a top-tier position as a diversified healthcare provider, competing directly with major domestic players such as YungShin Global Holding, China Chemical & Pharmaceutical (CCPC), and Standard Chem & Pharm. Unlike pure-play generic manufacturers, Sinphar distinguishes itself through its extensive investment in botanical drug R&D and a robust retail distribution network that bridges the gap between clinical medicine and consumer wellness. Founded in 1977 by Chairman Lee Chih-hsien, Sinphar remains under the strategic guidance of the Lee family, ensuring long-term continuity in its corporate vision. Lee Chih-hsien, a veteran of the Taiwanese pharmaceutical industry, has steered the company from a local manufacturer to a multinational group with significant footprints in China and North America. The executive leadership team includes General Manager Lee Yi-Hao, who oversees operational efficiency and the group’s expansion into high-growth biotech sectors. The board of directors is characterized by a mix of family leadership and industry experts, with significant influence from the Lee family’s holding entities. While primarily family-controlled, the company attracts institutional interest from domestic investment trusts and insurance funds drawn to its consistent dividend history and integrated supply chain. The leadership’s pedigree is rooted in a quality-first philosophy, evidenced by the company’s early adoption of PIC/S GMP standards and its strategic focus on proprietary extraction technologies for botanical ingredients.